2',5'-Oligoadenylate synthetase levels in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b do not correlate with clinical response.

In clinical trials with interferon alpha 2b (IFN-alpha 2b) as maintenance therapy for multiple myeloma, the therapeutic benefit is inconclusive. Although the mechanism(s) by which IFN-alpha 2b prolongs remission in some patients is unknown, 2',5'-oligoadenylate synthetase (2,5-A synthetase...

Descripción completa

Detalles Bibliográficos
Autores principales: Millar, B. C., Bell, J. B.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034066/
https://www.ncbi.nlm.nih.gov/pubmed/8519671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034066/
https://www.ncbi.nlm.nih.gov/pubmed/8519671

Ejemplares similares